This August, ClearView Healthcare Partners had the pleasure of welcoming Laurel Sweeney and Andy Molnar for a panel discussion on the challenges and strategic approaches to secure reimbursement for digital health technologies – thank you to both for participating!
As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?
RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?
What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?